|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 小鼠骨髓基质细胞Kusa-A1成骨分化中Notch信号相关基因表达分析显示文摘目的:检测骨髓基质细胞系Kusa-A1成骨分化过程中Notch信号相关分子的表达变化,分析Notch信号途径在成骨细胞分化和骨形成中的可能作用.方法:培养小鼠Kusa-A1细胞,在常规培养和诱导培养(添加维生素C和β磷酸甘油)条件下用Real-time PCR方法分别检测Delta1、Jagged1、Notch1、CBF1、HES1基因的表达变化.同时也检测了成骨标志基因骨桥蛋白(OPN)的表达变化.结果:常规培养下Kusa-A1细胞汇片后0~5d,OPN表达有轻微下调,Notch相关分子表达维持不变或有轻微下调.诱导培养条件下细胞汇片后0~5d,OPN表达上调,而Delta1、Jagged1、Notch1、HES1表达大幅度下调,惟有CBF1表达有轻度上调趋势.结论:Notch信号分子表达与Kusa-A1细胞成骨分化负相关,Notch信号对细胞成骨分化可能有抑制作用,而CBF1则可能对成骨细胞分化有正向调节作用. | 王胜朝 Kawashima Nobuyuki Sakamoto Kei Suda Hideaki 史俊南 | 2005 | 口腔医学研究2005，21，4： | 7 |
| 2 | Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication:A randomized study in Japan显示文摘AIM:To find the way to improve the eradication rate of first-line therapy in Japanese patients.METHODS:We prospectively compared the effectiveness of 7-d quadruple therapy to standard 7 d triple therapy in Japanese patients infected with Helicobacter pylori(H.pylori).One hundred and nineteen patients were randomly assigned to receive 7-d non-bismuth quadruple therapy with lansoprazole,amoxicillin,clarithromycin and metronidazole(LACM7) or 7-d triple therapy with lansoprazole,amoxicillin and clarithromycin(LAC7).After three months,H.pylori status was analyzed by 13C-urea breath test.Incidence rates of adverse events were evaluated by use of questionnaires.RESULTS:By intention-to-treat(ITT) analysis,the eradication rate in the LACM7 group was 94.9%,which was significantly higher than the LAC7 group(68.3%,P < 0.001).Per protocol analysis also showed a significantly higher eradication rate in the LACM7 group(98.3%) than the LAC7 group(73.2%,P < 0.001).Nevertheless,the incidence of serious adverse events did not differ between the two groups(RR:1.10,95% CI:0.70-1.73,P = 0.67).CONCLUSION:Seven day non-bismuth quadruple therapy(LACM7) was superior to standard 7-d triple therapy(LAC7) for first-line eradication. | Ayako Yanai Kei Sakamoto Masao Akanuma Keiji Ogura Shin Maeda | 2012 | World Journal of Gastrointestinal Pharmacology and Therapeutics2012，3，1： | 5 |
| 3 | Distribution of HBV genotypes among HBV carriers in Benin:phylogenetic analysis and virological characteristics of HBV genotype E显示文摘AIM: To determine the distribution of Hepatitis B virus (HBV) genotypes in Benin, and to clarify the virological characteristics of the dominant genotype.METHODS: Among 500 blood donors in Benin, 21 HBsAg-positive donors were enrolled in the study. HBV genotypes were determined by enzyme immunoassay and restriction fragment length polymorphism. Complete genome sequences were determined by PCR and direct sequencing.RESULTS: HBV genotype E (HBV/E) was detected in 20/21 (95.2%), and HBV/A in 1/21 (4.8%). From the age-specific prevalence of HBeAg to anti-HBe seroconversion (SC) in 19 HBV/E subjects, SC was estimated to occur frequently in late teens in HBV/E.The comparison of four complete HBV/E genomes from HBeAg-positive subjects in this study and five HBV/E sequences recruited from the database revealed that HBV/E was distributed throughout West Africa with very low genetic divers ity (nucleotide homology 96.7-99.2%).Based on the sequences in the basic core promoter (BCP)to precore region of the nine HBV/E isolates compared to those of the other genotypes, a nucleotide substitution in the BCP, G1757A, was observed in HBV/E.CONCLUSION: HBV/E is predominant in the Republic of Benin, and SC is estimated to occur in late teens in HBV/E. The specific nucleotide substitution G1757A in BCP, which might influence the virological characteristics,is observed in HBV/E. | Kei Fujiwara Yasuhito Tanaka Etsuro Orito Tomoyoshi Ohno Takanobu Kato Kanji Sugihara Izumi Hasegawa Mayumi Sakurai Kiyoaki Ito Atsushi Ozasa Yuko Sakamoto Isao Arita Ahmed El-Gohary Agossou Benoit Sophie I Ogoundele-Akplogan Namiko Yoshihara Ryuzo Ueda Masashi Mizokami | 2005 | World Journal of Gastroenterology2005，11，41： | 3 |
| 4 | Study protocol of the Asian XELIRI ProjecT(AXEPT):a multinational,randomized,non-inferiority,phase Ⅲ trial of second-line chemotherapy for metastatic colorectal cancer, comparing the eicacy and safety of XELIRI with or without bevacizumab versus FOLFIRI w显示文摘Background: Capecitabine and irinotecan combination therapy(XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer(m CRC). Recently, in the Association of Medical Oncology of the German Cancer Society(AIO) 0604 trial, tri?weekly XELIRI plus bevacizumab, with reduced doses of irinotecan(200 mg/m^2 on day 1) and capecitabine(1600 mg/m^2 on days 1–14), repeated every 3 weeks, has shown favorable tolerability and eicacy which were comparable to those of capecitabine and oxaliplatin(XELOX) plus bevacizumab. The doses of capecit?abine and irinotecan in the AIO trial are considered optimal. In a phase I/II study, XELIRI plus bevacizumab(BIX) as second?line chemotherapy was well tolerated and had promising eicacy in Japanese patients.Methods: The Asian XELIRI Projec T(AXEPT) is an East Asian collaborative, open?labelled, randomized, phase Ⅲ clinical trial which was designed to demonstrate the non?inferiority of XELIRI with or without bevacizumab versus standard FOLFIRI(5?fluorouracil, leucovorin, and irinotecan combination) with or without bevacizumab as second?line chemo?therapy for patients with m CRC. Patients with 20 years of age or older, histologically conirmed m CRC, Eastern Coop?erative Oncology Group performance status 0–2, adequate organ function, and disease progression or intolerance of the irst?line regimen will be eligible. Patients will be randomized(1:1) to receive standard FOLFIRI with or with?out bevacizumab(5 mg/kg on day 1), repeated every 2 weeks(FOLIRI arm) or XELIRI with or without bevacizumab(7.5 mg/kg on day 1), repeated every 3 weeks(XELIRI arm). A total of 464 events were estimated as necessary to show non?inferiority with a power of 80% at a one?sided α of 0.025, requiring a target sample size of 600 patients. The 95% conidence interval(CI) upper limit of the hazard ratio was pre?speciied as less than 1.3.Conclusion: The Asian XELIRI Projec T is a multinational phase III trial being conducted to provide evidence for XELIRI with or without bevacizumab as a second?line treatment option of mCRC. | Masahito Kotaka Ruihua Xu Kei Muro Young Suk Park Satoshi Morita Satoru Iwasa Hiroyuki Uetake Tomohiro Nishina Hiroaki Nozawa Hiroshi Matsumoto Kentaro Yamazaki Sae-Won Han Wei Wang Joong Bae Ahn Yanhong Deng Sang-Hee Cho Yi Ba Keun-Wook Lee Tao Zhang Taroh Satoh Marc E.Buyse Baek-Yeol Ryoo Lin Shen Junichi Sakamoto Tae Won Kim | 2016 | Chinese Journal of Cancer2016，35，12： | 3 |
| 5 | Aspirin Inhibits mTOR Signaling, Activates AMP-Activated Protein Kinase, and Induces Autophagy in Colorectal Cancer Cells显示文摘 | Farhat V.N. Din Asta Valanciute Vanessa P. Houde Daria Zibrova Kevin A. Green Kei Sakamoto Dario R. Alessi Malcolm G. Dunlop | 2012 | Gastroenterology2012，，7： | 3 |
| 6 | Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state显示文摘 | Foretz Marc Hébrard Sophie Leclerc Jocelyne Zarrinpashneh Elham Soty Maud Mithieux Gilles Sakamoto Kei Andreelli Fabrizio Viollet Benoit | 2010 | Journal of Clinical Investigation2010，，7： | 2 |
| 7 | 转录调控因子CBF1(RBP-Jκ)对Cbfa1和Ose2元件启动子活性的影响显示文摘目的探讨Notch信号转录调控因子CBF1(RBP-Jκ)对核心结合因子Cbfa1基因启动子和骨钙素基因启动子区域Ose2元件启动子活性的影响。方法构建CBF1真核表达载体pCMV-Tag4/CBF1;将梯度浓度pCMV-Tag4/CBF1和荧光素酶报告质粒共转染两成骨前体细胞系Kusa-A1和Kusa-O,用双荧光素酶报告基因方法检测Cbfa1和Ose2元件启动子活性。结果随CBF1浓度增加,Kusa-A1和Kusa-O细胞中Cbfa1和Ose2元件启动子活性均逐渐提高。统计分析表明Kusa-A1细胞中1/40μg/μL实验组两启动子活性均与对照组差异显著;Kusa-O细胞中1/40μg/μL实验组Ose2元件启动子活性与对照组差异显著。结论转录调控因子CBF1可以促进Cbfa1和Ose2元件启动子活性,从而可能对细胞的成骨性分化有正调节作用。 | 王胜朝 KAWASHIMA Nobuyuki SAKAMOTO Kei KATSUBE Ken-Ichi SHINDO Kentaro TAKAGI Minoru SUDA Hideaki 史俊南 | 2004 | 牙体牙髓牙周病学杂志2004，14，12： | 2 |
| 8 | CXCL12 secreted from glioma stem cells regulates their proliferation显示文摘 | Youji Uemae Eiichi Ishikawa Satoru Osuka Masahide Matsuda Noriaki Sakamoto Shingo Takano Kei Nakai Tetsuya Yamamoto Akira Matsumura | 2014 | Journal of Neuro-Oncology2014，，1： | 1 |
| 9 | Electricity producing property and bacterial community structure in microbial fuel cell equipped with membrane electrode assembly显示文摘 | Owen Rubaba Yoko Araki Shuji Yamamoto Kei Suzuki Hisatoshi Sakamoto Atsunori Matsuda Hiroyuki Futamata | 2013 | Journal of Bioscience and Bioengineering2013，，1： | 1 |
| 10 | Influence of Pre-Exercise Muscle Temperature on Responses to Eccentric Exercise显示文摘 | Kazunori Nosaka Kei Sakamoto Mike Newton | | 0，，02： | 1 |
| 11 | Exercise effects on muscle insulin signaling and actioninvited review:Intracellular signaling in contracting skeletal muscle显示文摘 | Kei Sakamoto | 2002 | J Appl Physiol2002，93，： | 1 |
| 12 | Exercise effects on muscle insulin signaling and actioninvited review: Intracellular signaling in contracting skeletal muscle显示文摘 | Kei Sakamoto | 2002 | J Appl Physiol2002，93，： | 1 |
| 13 | Expression of angiogenic factors in hepatocarcinogenesis: Identificationby antibody arrays显示文摘 | Takako Nomura Asahiro Morishita Gong Jian Shima Mimura Kiyohito Kato Kei Nomura Joji Tani Hisaaki Miyoshi Hirohito Yoneyama Teppei Sakamoto Koji Fujita Emiko Maeda Hideki Kobara Hirohito Mori Hisakazu Iwama Tsutomu Masaki | 2013 | Oncology Reports2013，，5： | 1 |
| 14 | Exercise effects on muscle insulin signaling and action 显示文摘 | KEI SAKAMOTO LAURIE J | 2002 | Appl Physiol2002，93，4： | 1 |
| 15 | Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer:a post hoc analysis of the AXEPT study显示文摘Dear Editor,Recently,the phase III Asian XELIRI(capecitabine plus irinotecan)ProjecT(AXEPT)study demonstrated the non-inferiority of modified capecitabine plus irinotecan(mXELIRI)±bevacizumab(Bev)to fluorouracil plus leucovorin with irinotecan(FOLFIRI)±Bev in terms of overall survival(OS)as a second-line treatment for patients with metastatic colorectal cancer[1,2].In the past decade,oral prodrugs of fluorouracil-containing regimens have shown similar efficacies to intravenous fluorouracilcontaining regimens. | Satoru Iwasa Zi-Xian Wang Kei Muro Satoshi Morita Young Suk Park Dongsheng Zhang Yasuhide Yamada Junichi Sakamoto TaeWon Kim | 2023 | Cancer Communications2023，43，4： | 1 |
| 16 | Cut off and weakening processes of an upper cold low显示文摘 | Sakamoto Kei | 2005 | J Meteor Soc Japan2005，83，： | 1 |
| 17 | Ursodeoxycholic Acid Protects Hepatocytes against Oxidative Injury via Induction of Antioxidants显示文摘 | Hironori Mitsuyoshi Toshiaki Nakashima Yoshio Sumida Takaharu Yoh Yoshiki Nakajima Hiroki Ishikawa Koji Inaba Yoshikuni Sakamoto Takeshi Okanoue Kei Kashima | 1999 | Biochemical and Biophysical Research Communications1999，，2： | 1 |
| 18 | Side effects of high-dose interferon therapy for chronic hepatitis C显示文摘 | Takeshi Okanoue Shinichi Sakamoto Yoshito Itoh Masahito Minami Koichiro Yasui Masafumi Sakamoto Kenichi Nishioji Tatsuo Katagishi Yoshihiro Nakagawa Hisashi Tada Yoshihiko Sawa Masayuki Mizuno Keizo Kagawa Kei Kashima | 1996 | Journal of Hepatology1996，，3： | 1 |
| 19 | Carcinogenesis of Intraductal Papillary Mucinous Neoplasm of the Pancreas: Loss of MicroRNA-101 Promotes Overexpression of Histone Methyltransferase EZH2显示文摘 | Osamu Nakahara Hiroshi Takamori Masaaki Iwatsuki Yoshifumi Baba Yasuo Sakamoto Hiroshi Tanaka Akira Chikamoto Kei Horino Toru Beppu Keiichiro Kanemitsu Yumi Honda Ken-ichi Iyama Hideo Baba | 2012 | Annals of Surgical Oncology2012，，3： | 1 |
| 20 | LKB1-DEPENDENT SIGNALING PATHWAYS显示文摘 | Dario R. Alessi Kei Sakamoto Jose R. Bayascas | 2006 | Annual Review of Biochemistry2006，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员